Survivor mHealth: Wearable Devices in Cancer Survivors

Sponsor
University of Massachusetts, Worcester (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05417438
Collaborator
National Cancer Institute (NCI) (NIH), National Heart, Lung, and Blood Institute (NHLBI) (NIH)
40
1
1
6.5
6.1

Study Details

Study Description

Brief Summary

The Survivor mobile health (mHealth) study is testing the use of wearable devices (Fitbits) and a smartphone application in cancer survivors. The goal of the program is to increase survivor's physical activity levels. The Fitbit will be synced to the app and participants will receive messages and notifications about their activity levels. Participants will also complete surveys through the app asking how useful it is and ways to improve it. The study team will conduct qualitative interviews at the completion of the 3 months to see how participants liked the program, and ways it can be improved and make it more specific to cancer survivors. The study team will also conduct interviews with providers and clinic staff to assess their perceptions of patient digital health programs and preferences for receiving patient-generated health data.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Wearable device deployment
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Survivor mHealth: Assessing Feasibility of a Wearable Device and App in Cancer Survivors
Anticipated Study Start Date :
Jun 15, 2022
Anticipated Primary Completion Date :
Oct 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wearable device deployment

Participants will be enrolled in the experimental trial to receive Fitbits and a smartphone app.

Behavioral: Wearable device deployment
Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of enrollment [Baseline]

    Feasibility will be determined by a participant meeting all three criteria: 1) Enrollment in trial, 2) completion of baseline measures, and 3) Fitbit sync to app.

Secondary Outcome Measures

  1. Changes in objective physical activity [At study completion, within 3-months of enrollment]

    Change from baseline to 3-months in steps, light, moderate and vigorous physical activity measured via Fitbits.

  2. Changes in self-report physical activity [At study completion, within 3-months of enrollment]

    Change from baseline to 3-months in light, moderate and vigorous physical activity survey-measured (Godin leisure time questionnaire) physical activity. The questionnaire is a 4-item self-administered questionnaire with the first three questions seeking information on the number of times one engages in mild, moderate and strenuous leisure-time physical activity bouts of at least 15 min duration in a typical week. Scores can range from 0 to 98, with the higher score meaning a greater level of activity for that week.

  3. Changes in quality of life [At study completion, within 3 months of referral completion]

    The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item questionnaire assessing physical, emotional, social, and functional well-being over the past 7 days. Participants respond on a Likert scale of 0 to 4 (0=Not at all, 4=Very much). Scores are summed to a total of 0-108 points, with a higher score indicating a greater quality of life.

  4. Usability [1-month and 3-months post-enrollment]

    Mobile Application Rating Scale (MARS). The Rating scale assesses app quality on four dimensions. All items are rated on a 5-point scale from "1.Inadequate" to "5.Excellent". A higher score indicates greater user acceptability of the app.

  5. 1-Month Usability [1-month post-enrollment]

    Mobile Application Rating Scale (MARS). The Rating scale assesses app quality on four dimensions. All items are rated on a 5-point scale from "1.Inadequate" to "5.Excellent". A higher score indicates greater user acceptability of the app.

  6. 3-Month Usability [3-months post-enrollment]

    Mobile Application Rating Scale (MARS). The Rating scale assesses app quality on four dimensions. All items are rated on a 5-point scale from "1.Inadequate" to "5.Excellent". A higher score indicates greater user acceptability of the app.

  7. Participant program acceptability [At study completion, within 3 months of referral completion]

    Qualitative feedback from enrolled participants on the acceptability of the Fitbits, app, mobile questionnaires, and push notification messages within the app

Other Outcome Measures

  1. Provider acceptability of wearable devices and preferences to receive data [At study completion; Within 3-month of last patient enrolled]

    Qualitative feedback from providers on their preferences for patients using wearable devices and receiving patient-generated data

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Aims 1 and 2 Inclusion Criteria:
  1. Past cancer diagnosis

  2. At least 18 years of age

  3. Capacity to provide informed consent

  4. Medically cleared to perform physical activity (as noted by Physical Activity Readiness Questionnaire form or physician's clearance if needed)

  5. Owns a smartphone

Aims 1 and 2 Exclusion Criteria:
  1. Is a prisoner

  2. Non-English speaking

  3. Is unable to provide consent

  4. Under 18 years of age

  5. No prior cancer diagnosis

  6. Does not own a smartphone

Aim 3 Inclusion Criteria:
  1. Are a current UMass Memorial Cancer Clinic patient navigator, oncologist, radiologist, or cardiologist

  2. Consent to participate

Aim 3 Exclusion Criteria:
  1. Not currently employed at UMass Memorial

  2. Not involved in direct treatment of care coordination of cancer patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Massachusetts Chan Medical School Worcester Massachusetts United States 01605

Sponsors and Collaborators

  • University of Massachusetts, Worcester
  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Jamie M Faro, PhD, University of Massachusetts Chan Medical School

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jamie Faro, Assistant Professor, University of Massachusetts, Worcester
ClinicalTrials.gov Identifier:
NCT05417438
Other Study ID Numbers:
  • H00023545
  • 5P50CA244693-02
  • 1K12HL138049-01
First Posted:
Jun 14, 2022
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jamie Faro, Assistant Professor, University of Massachusetts, Worcester
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022